Literature DB >> 10548316

Vasectomy and risk of prostate cancer.

J L Stanford1, K G Wicklund, B McKnight, J R Daling, M K Brawer.   

Abstract

Most studies do not support an association between vasectomy and prostate cancer, but a few have suggested a link. Vasectomy is a common birth control method, and prostate cancer is the most frequently diagnosed solid tumor in men, making this a major public health question. This study was specifically designed to determine whether or not vasectomy is associated with risk of prostate cancer. To examine this issue, we conducted a population-based case-control study in King County, Washington. Interviews were completed with men ages 40-64 years newly diagnosed with prostate cancer between January 1993 and December 1996 who were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) cancer registry (n = 753) and with comparison men without prostate cancer identified from the same general population (n = 703). The odds ratio (OR) for prostate cancer in relation to vasectomy was assessed. The prevalence of vasectomy was similar in cases (39.4%) and controls (37.7%), resulting in no association (adjusted OR, 1.10; 95% confidence interval, 0.9-1.4). There was no consistent evidence that risk varied by the age at which vasectomy was performed, the time since vasectomy, or the calendar period when the vasectomy was performed. The OR in relation to vasectomy was higher in men with less aggressive prostate cancer. Risk estimates did not differ according to age, race, or family history of prostate cancer. This study suggests that vasectomy is not associated with the risk of developing prostate cancer. It also provides evidence that vasectomized men may be more likely to present with earlier-stage, lower-grade prostate tumors.

Entities:  

Mesh:

Year:  1999        PMID: 10548316

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  71 in total

1.  CYP17 polymorphisms and prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Daniel W Lin; Suzanne Kolb; Joseph S Koopmeiners; Ziding Feng; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

2.  The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Bimal Bhindi; Christopher J D Wallis; Madhur Nayan; Ann M Farrell; Landon W Trost; Robert J Hamilton; Girish S Kulkarni; Antonio Finelli; Neil E Fleshner; Stephen A Boorjian; R Jeffrey Karnes
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

3.  Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.

Authors:  Shanshan Zhao; Milan S Geybels; Amy Leonardson; Rohina Rubicz; Suzanne Kolb; Qingxiang Yan; Brandy Klotzle; Marina Bibikova; Antonio Hurtado-Coll; Dean Troyer; Raymond Lance; Daniel W Lin; Jonathan L Wright; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Janet L Stanford
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

4.  DNA methylation profiles in African American prostate cancer patients in relation to disease progression.

Authors:  Rohina Rubicz; Shanshan Zhao; Milan Geybels; Jonathan L Wright; Suzanne Kolb; Brandy Klotzle; Marina Bibikova; Dean Troyer; Raymond Lance; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford
Journal:  Genomics       Date:  2016-02-21       Impact factor: 5.736

5.  Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.

Authors:  Milan S Geybels; Shanshan Zhao; Chao-Jen Wong; Marina Bibikova; Brandy Klotzle; Michael Wu; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Janet L Stanford
Journal:  Prostate       Date:  2015-09-18       Impact factor: 4.104

6.  Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.

Authors:  Milan S Geybels; Karen D McCloskey; Ian G Mills; Janet L Stanford
Journal:  Prostate       Date:  2016-10-18       Impact factor: 4.104

7.  Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.

Authors:  Ilir Agalliu; Erika M Kwon; Claudia A Salinas; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Causes Control       Date:  2009-11-10       Impact factor: 2.506

8.  Raman and coherent anti-Stokes Raman scattering microscopy studies of changes in lipid content and composition in hormone-treated breast and prostate cancer cells.

Authors:  Mariana C Potcoava; Gregory L Futia; Jessica Aughenbaugh; Isabel R Schlaepfer; Emily A Gibson
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

9.  Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

10.  Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.

Authors:  Jonathan L Wright; Claudia A Salinas; Daniel W Lin; Suzanne Kolb; Joseph Koopmeiners; Ziding Feng; Janet L Stanford
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.